A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
NCT06908928
This study is recruiting at 6 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Triple Negative Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Last updated on ClinicalTrials.gov
- March 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- City of Hope · Duarte, CA
- UCSD Moores Cancer Center · La Jolla, CA
Colorado · 1
- Anschutz Medical Center · Aurora, CO
Illinois · 1
- UChicago Medicine Comprehensive Cancer Center · Chicago, IL
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
New York · 1
- Memorial Sloan Kettering Cancer Center · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.